1. Fungemia due to Fusarium solani under low-dose liposomal amphotericin B in a patient after cord blood transplantation
- Author
-
Yoshiki Misawa, Masamichi Isobe, Shunsuke Takahashi, Arinobu Tojo, Satoshi Takahashi, Mai Mizusawa, Koji Jimbo, Takaaki Konuma, Tomohiko Kiyuna, Seiko Kato, and Masato Suzuki
- Subjects
Male ,0301 basic medicine ,Microbiology (medical) ,Fusariosis ,Fusarium ,Antifungal Agents ,medicine.medical_treatment ,030106 microbiology ,Virulence ,Hematopoietic stem cell transplantation ,Microbiology ,03 medical and health sciences ,0302 clinical medicine ,Amphotericin B ,medicine ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Fungemia ,Aged ,biology ,business.industry ,food and beverages ,equipment and supplies ,bacterial infections and mycoses ,medicine.disease ,biology.organism_classification ,Lymphoma ,Infectious Diseases ,Cord Blood Stem Cell Transplantation ,business ,Fusarium solani ,medicine.drug - Abstract
The introduction of the prophylactic use of antifungal drugs caused the increased occurrence of invasive fungal infections due to previously rare molds, such as fusariosis, after allogeneic hematopoietic stem cell transplantation. We herein report the case of a patient with diffuse large B-cell lymphoma who developed fungemia due to Fusarium solani during liposormal amphotericin B on day 25 after cord blood transplantation (CBT). Because Fusarium species might differ in virulence and drug susceptibility, the sequencing of the internal transcribed spacer region of the ribosomal RNA gene accurately identified Fusarium solani to be the cause of fungemia at the species level. This case highlights Fusarium solani as the cause of fungemia in a patient under liposormal amphotericin B treatment after CBT.
- Published
- 2019